GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (FRA:ILA) » Definitions » Common Stock

Imugene (FRA:ILA) Common Stock : €228.79 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Imugene Common Stock?

Imugene's quarterly common stock increased from Dec. 2023 (€224.25 Mil) to Jun. 2024 (€228.43 Mil) and increased from Jun. 2024 (€228.43 Mil) to Dec. 2024 (€228.79 Mil).

Imugene's annual common stock increased from Jun. 2022 (€153.43 Mil) to Jun. 2023 (€197.70 Mil) and increased from Jun. 2023 (€197.70 Mil) to Jun. 2024 (€228.43 Mil).


Imugene Common Stock Historical Data

The historical data trend for Imugene's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imugene Common Stock Chart

Imugene Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.87 71.77 153.43 197.70 228.43

Imugene Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 200.93 197.70 224.25 228.43 228.79

Imugene Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Imugene Business Description

Traded in Other Exchanges
Address
4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

Imugene Headlines

No Headlines